Literature DB >> 12607680

Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use.

Norbert Lubenow1, Sixten Selleng, Hans-Georg Wollert, Petra Eichler, Bernd Müllejans, Andreas Greinacher.   

Abstract

Heparin-induced thrombocytopenia (HIT), a serious complication of heparin therapy, mandates heparin cessation and alternative anticoagulation. We report a patient with a history of HIT who successfully underwent cardiopulmonary bypass (CPB) using short-term reexposure to heparin and perioperative therapy with argatroban. No bleeding complications or HIT-related problems occurred. The pharmacokinetics of argatroban, especially its hepatic rather than renal elimination, makes it the drug of choice for some HIT patients in whom other alternative anticoagulants (eg, danaparoid and hirudin) are less well suited. Because of interference with the international normalized ratio (INR), switching from argatroban to oral anticoagulants is not straightforward.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12607680     DOI: 10.1016/s0003-4975(02)04309-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Thrombin inhibitors and cardiopulmonary bypass.

Authors:  Alan Merry
Journal:  J Extra Corpor Technol       Date:  2006-03

2.  Safety and efficacy of the argatroban therapy during the early post-cardiac surgery period.

Authors:  Joo Heung Yoon; Robert W Yeh; Kyung Hun Nam; William D Hoffman; Arvind K Agnihotri; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

3.  [Patient with heparin-induced thrombocytopenia type II and implanted left ventricular assist device].

Authors:  J T Lutz; H J Exner; A Schannewitzky; W Fehske; K Görlinger
Journal:  Anaesthesist       Date:  2008-01       Impact factor: 1.041

Review 4.  Heparin-induced thrombocytopenia: a renal perspective.

Authors:  Samaha Syed; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

Review 5.  [Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia].

Authors:  S A Kozek-Langenecker
Journal:  Anaesthesist       Date:  2008-06       Impact factor: 1.041

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.